^
Association details:
| Biomarker: | XPO1 E571K |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1341 - Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 and SF3B1 mutant hematologic malignancies
Published date:
03/10/2021
Excerpt:
Five lymphoma cell lines; 3 diffuse large B-cell lymphoma (SU-DHL-6, SU-DHL-16, FARAGE) and 2 classical Hodgkin lymphoma (L428 and SUP-HD1), were used based on the presence or absence of XPO1 mutations. SUDHL-16 and SUP-HD1 are heterozygous for the XPO1 E571K hotspot mutation while SUDHL-6, FARAGE and SUP-HD1 are wildtype. These cell lines were used to assess sensitivity to Selinexor or Venetoclax using the CellTiter Glo assay. The XPO1 mutant cells showed increased sensitivity to selinexor (IC50 = 16-35nM vs 41-231nM).
